These medications should also be avoided in patients with a history of acute or chronic pancreatitis, which is a painful and potentially fatal inflammation of the pancreas
Simultaneously, these medications suppress glucagon secretion from pancreatic alpha cells, reducing hepatic glucose production
DPP-4 degrades GLP-1 (7-36) into the non insulinotropic GLP-1 (9-36) (some studies suggest it may have weak insulinotropic activity)
The brain works to detect when the body is in need of a meal throughout the day
Temporal Changes in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use in Patients with Chronic Kidney Disease and Type 2 Diabetes, 20122023: A US Cohort Study
In recent months, Eli Lilly, the maker of Zepbound and Mounjaro, and Novo Nordisk, the maker of Ozempic and Wegovy, have each said that they are able to meet the demand for the medications after facing shortages since 2022 due to the drugs' growing popularity